recombinant tweak Search Results


94
R&D Systems recombinant murine tweak
Recombinant Murine Tweak, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant murine tweak/product/R&D Systems
Average 94 stars, based on 1 article reviews
recombinant murine tweak - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

94
R&D Systems recombinant human tweak tnfsf12
Recombinant Human Tweak Tnfsf12, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human tweak tnfsf12/product/R&D Systems
Average 94 stars, based on 1 article reviews
recombinant human tweak tnfsf12 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

92
R&D Systems fn14 decoy receptor
Fig. 4. <t>FN14</t> decoy receptor modulates the cytokine profile in CNV and reduces neovascularization size. (A): Experimental setup. (B): Intravitreal injection of a FN14 decoy receptor compared to PBS (control) significantly reduced CNV size. For statistical analysis, Mann–Whitney U test was applied. Color fundus (CF) and fluo rescence angiography (FA) on d7 of representative eyes of the FN14 decoy receptor (upper panel) and the PBS group (lower panel) as well as confocal microscopy (CM) images of representative lesions (COL4 in red) the size of which approximately corresponds to the mean spot size within the respective group. (C): Protein concentrations of several cytokines on d5 in the RPE of unlasered controls, CNV injected with PBS (CNV) or with FN14 decoy receptor on d1 (CNV + decoy). Data are shown as mean with SEM. For statistical analysis, paired ANOVA adjusting for total protein concentration was applied. *: p < 0.05, ns: not significant.
Fn14 Decoy Receptor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fn14 decoy receptor/product/R&D Systems
Average 92 stars, based on 1 article reviews
fn14 decoy receptor - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

93
R&D Systems recombinant human tweak
Fig. 4. <t>FN14</t> decoy receptor modulates the cytokine profile in CNV and reduces neovascularization size. (A): Experimental setup. (B): Intravitreal injection of a FN14 decoy receptor compared to PBS (control) significantly reduced CNV size. For statistical analysis, Mann–Whitney U test was applied. Color fundus (CF) and fluo rescence angiography (FA) on d7 of representative eyes of the FN14 decoy receptor (upper panel) and the PBS group (lower panel) as well as confocal microscopy (CM) images of representative lesions (COL4 in red) the size of which approximately corresponds to the mean spot size within the respective group. (C): Protein concentrations of several cytokines on d5 in the RPE of unlasered controls, CNV injected with PBS (CNV) or with FN14 decoy receptor on d1 (CNV + decoy). Data are shown as mean with SEM. For statistical analysis, paired ANOVA adjusting for total protein concentration was applied. *: p < 0.05, ns: not significant.
Recombinant Human Tweak, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human tweak/product/R&D Systems
Average 93 stars, based on 1 article reviews
recombinant human tweak - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

85
Kingfisher Biotech untagged recombinant mouse tweak
Fig. 4. <t>FN14</t> decoy receptor modulates the cytokine profile in CNV and reduces neovascularization size. (A): Experimental setup. (B): Intravitreal injection of a FN14 decoy receptor compared to PBS (control) significantly reduced CNV size. For statistical analysis, Mann–Whitney U test was applied. Color fundus (CF) and fluo rescence angiography (FA) on d7 of representative eyes of the FN14 decoy receptor (upper panel) and the PBS group (lower panel) as well as confocal microscopy (CM) images of representative lesions (COL4 in red) the size of which approximately corresponds to the mean spot size within the respective group. (C): Protein concentrations of several cytokines on d5 in the RPE of unlasered controls, CNV injected with PBS (CNV) or with FN14 decoy receptor on d1 (CNV + decoy). Data are shown as mean with SEM. For statistical analysis, paired ANOVA adjusting for total protein concentration was applied. *: p < 0.05, ns: not significant.
Untagged Recombinant Mouse Tweak, supplied by Kingfisher Biotech, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/untagged recombinant mouse tweak/product/Kingfisher Biotech
Average 85 stars, based on 1 article reviews
untagged recombinant mouse tweak - by Bioz Stars, 2026-02
85/100 stars
  Buy from Supplier

90
R&D Systems human tweak
Fig. 4. <t>FN14</t> decoy receptor modulates the cytokine profile in CNV and reduces neovascularization size. (A): Experimental setup. (B): Intravitreal injection of a FN14 decoy receptor compared to PBS (control) significantly reduced CNV size. For statistical analysis, Mann–Whitney U test was applied. Color fundus (CF) and fluo rescence angiography (FA) on d7 of representative eyes of the FN14 decoy receptor (upper panel) and the PBS group (lower panel) as well as confocal microscopy (CM) images of representative lesions (COL4 in red) the size of which approximately corresponds to the mean spot size within the respective group. (C): Protein concentrations of several cytokines on d5 in the RPE of unlasered controls, CNV injected with PBS (CNV) or with FN14 decoy receptor on d1 (CNV + decoy). Data are shown as mean with SEM. For statistical analysis, paired ANOVA adjusting for total protein concentration was applied. *: p < 0.05, ns: not significant.
Human Tweak, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human tweak/product/R&D Systems
Average 90 stars, based on 1 article reviews
human tweak - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
R&D Systems human fc domain
Fig. 4. <t>FN14</t> decoy receptor modulates the cytokine profile in CNV and reduces neovascularization size. (A): Experimental setup. (B): Intravitreal injection of a FN14 decoy receptor compared to PBS (control) significantly reduced CNV size. For statistical analysis, Mann–Whitney U test was applied. Color fundus (CF) and fluo rescence angiography (FA) on d7 of representative eyes of the FN14 decoy receptor (upper panel) and the PBS group (lower panel) as well as confocal microscopy (CM) images of representative lesions (COL4 in red) the size of which approximately corresponds to the mean spot size within the respective group. (C): Protein concentrations of several cytokines on d5 in the RPE of unlasered controls, CNV injected with PBS (CNV) or with FN14 decoy receptor on d1 (CNV + decoy). Data are shown as mean with SEM. For statistical analysis, paired ANOVA adjusting for total protein concentration was applied. *: p < 0.05, ns: not significant.
Human Fc Domain, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human fc domain/product/R&D Systems
Average 90 stars, based on 1 article reviews
human fc domain - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

86
R&D Systems mouse recombinant tweak
Fig. 4. <t>FN14</t> decoy receptor modulates the cytokine profile in CNV and reduces neovascularization size. (A): Experimental setup. (B): Intravitreal injection of a FN14 decoy receptor compared to PBS (control) significantly reduced CNV size. For statistical analysis, Mann–Whitney U test was applied. Color fundus (CF) and fluo rescence angiography (FA) on d7 of representative eyes of the FN14 decoy receptor (upper panel) and the PBS group (lower panel) as well as confocal microscopy (CM) images of representative lesions (COL4 in red) the size of which approximately corresponds to the mean spot size within the respective group. (C): Protein concentrations of several cytokines on d5 in the RPE of unlasered controls, CNV injected with PBS (CNV) or with FN14 decoy receptor on d1 (CNV + decoy). Data are shown as mean with SEM. For statistical analysis, paired ANOVA adjusting for total protein concentration was applied. *: p < 0.05, ns: not significant.
Mouse Recombinant Tweak, supplied by R&D Systems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse recombinant tweak/product/R&D Systems
Average 86 stars, based on 1 article reviews
mouse recombinant tweak - by Bioz Stars, 2026-02
86/100 stars
  Buy from Supplier

93
R&D Systems recombinant mouse tweak
Fig. 4. <t>FN14</t> decoy receptor modulates the cytokine profile in CNV and reduces neovascularization size. (A): Experimental setup. (B): Intravitreal injection of a FN14 decoy receptor compared to PBS (control) significantly reduced CNV size. For statistical analysis, Mann–Whitney U test was applied. Color fundus (CF) and fluo rescence angiography (FA) on d7 of representative eyes of the FN14 decoy receptor (upper panel) and the PBS group (lower panel) as well as confocal microscopy (CM) images of representative lesions (COL4 in red) the size of which approximately corresponds to the mean spot size within the respective group. (C): Protein concentrations of several cytokines on d5 in the RPE of unlasered controls, CNV injected with PBS (CNV) or with FN14 decoy receptor on d1 (CNV + decoy). Data are shown as mean with SEM. For statistical analysis, paired ANOVA adjusting for total protein concentration was applied. *: p < 0.05, ns: not significant.
Recombinant Mouse Tweak, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse tweak/product/R&D Systems
Average 93 stars, based on 1 article reviews
recombinant mouse tweak - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

90
R&D Systems recombinant human fn14 fc fusion protein
Fig. 4. <t>FN14</t> decoy receptor modulates the cytokine profile in CNV and reduces neovascularization size. (A): Experimental setup. (B): Intravitreal injection of a FN14 decoy receptor compared to PBS (control) significantly reduced CNV size. For statistical analysis, Mann–Whitney U test was applied. Color fundus (CF) and fluo rescence angiography (FA) on d7 of representative eyes of the FN14 decoy receptor (upper panel) and the PBS group (lower panel) as well as confocal microscopy (CM) images of representative lesions (COL4 in red) the size of which approximately corresponds to the mean spot size within the respective group. (C): Protein concentrations of several cytokines on d5 in the RPE of unlasered controls, CNV injected with PBS (CNV) or with FN14 decoy receptor on d1 (CNV + decoy). Data are shown as mean with SEM. For statistical analysis, paired ANOVA adjusting for total protein concentration was applied. *: p < 0.05, ns: not significant.
Recombinant Human Fn14 Fc Fusion Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human fn14 fc fusion protein/product/R&D Systems
Average 90 stars, based on 1 article reviews
recombinant human fn14 fc fusion protein - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

86
R&D Systems human recombinant tweak
cIAP-1 and cIAP-2 are downregulated in cholangiocytes of PSC patients. ( a ) Representative images of liver sections stained for cIAP-1 (left panel) and cIAP-2 (right panel) in patients with normal, NASH and PSC (stage IV) liver histology. Photomicrographs of small bile ducts (SBD) and large bile ducts (LBD) taken at × 20 magnification. The arrows point to the bile ducts. ( b ) Histological scoring for cIAP-1 in normal (5, 31), NASH (12, 120) and PSC (16, 131) patients and for cIAP-2 in normal (5, 31), NASH (12, 118) and PSC (16, 123) patients. Numbers in parentheses indicate total number of patients and total number of small and large bile ducts evaluated, respectively. Grade 0=no protein expression; grade 3=high protein expression. ** P <0.01, *** P <0.001. ( c ) Representative images of liver sections stained for <t>TWEAK</t> (left panel) and Fn14 (right panel) from patients with normal or PSC (stage IV) liver histology. Photomicrographs of small bile ducts and large bile ducts taken at × 40 and × 20 magnification, respectively. The arrows point to the bile ducts. ( d ) Immunoblot analysis showing expression of cIAP-1, cIAP-2 and actin (loading control) in H69 cells treated with human <t>recombinant</t> TWEAK (100 ng/ml) for the indicated times
Human Recombinant Tweak, supplied by R&D Systems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human recombinant tweak/product/R&D Systems
Average 86 stars, based on 1 article reviews
human recombinant tweak - by Bioz Stars, 2026-02
86/100 stars
  Buy from Supplier

90
Biogen Inc insect-cell-derived recombinant tweak
cIAP-1 and cIAP-2 are downregulated in cholangiocytes of PSC patients. ( a ) Representative images of liver sections stained for cIAP-1 (left panel) and cIAP-2 (right panel) in patients with normal, NASH and PSC (stage IV) liver histology. Photomicrographs of small bile ducts (SBD) and large bile ducts (LBD) taken at × 20 magnification. The arrows point to the bile ducts. ( b ) Histological scoring for cIAP-1 in normal (5, 31), NASH (12, 120) and PSC (16, 131) patients and for cIAP-2 in normal (5, 31), NASH (12, 118) and PSC (16, 123) patients. Numbers in parentheses indicate total number of patients and total number of small and large bile ducts evaluated, respectively. Grade 0=no protein expression; grade 3=high protein expression. ** P <0.01, *** P <0.001. ( c ) Representative images of liver sections stained for <t>TWEAK</t> (left panel) and Fn14 (right panel) from patients with normal or PSC (stage IV) liver histology. Photomicrographs of small bile ducts and large bile ducts taken at × 40 and × 20 magnification, respectively. The arrows point to the bile ducts. ( d ) Immunoblot analysis showing expression of cIAP-1, cIAP-2 and actin (loading control) in H69 cells treated with human <t>recombinant</t> TWEAK (100 ng/ml) for the indicated times
Insect Cell Derived Recombinant Tweak, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/insect-cell-derived recombinant tweak/product/Biogen Inc
Average 90 stars, based on 1 article reviews
insect-cell-derived recombinant tweak - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Fig. 4. FN14 decoy receptor modulates the cytokine profile in CNV and reduces neovascularization size. (A): Experimental setup. (B): Intravitreal injection of a FN14 decoy receptor compared to PBS (control) significantly reduced CNV size. For statistical analysis, Mann–Whitney U test was applied. Color fundus (CF) and fluo rescence angiography (FA) on d7 of representative eyes of the FN14 decoy receptor (upper panel) and the PBS group (lower panel) as well as confocal microscopy (CM) images of representative lesions (COL4 in red) the size of which approximately corresponds to the mean spot size within the respective group. (C): Protein concentrations of several cytokines on d5 in the RPE of unlasered controls, CNV injected with PBS (CNV) or with FN14 decoy receptor on d1 (CNV + decoy). Data are shown as mean with SEM. For statistical analysis, paired ANOVA adjusting for total protein concentration was applied. *: p < 0.05, ns: not significant.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Article Title: Comparative transcriptome analysis of human and murine choroidal neovascularization identifies fibroblast growth factor inducible-14 as phylogenetically conserved mediator of neovascular age-related macular degeneration.

doi: 10.1016/j.bbadis.2022.166340

Figure Lengend Snippet: Fig. 4. FN14 decoy receptor modulates the cytokine profile in CNV and reduces neovascularization size. (A): Experimental setup. (B): Intravitreal injection of a FN14 decoy receptor compared to PBS (control) significantly reduced CNV size. For statistical analysis, Mann–Whitney U test was applied. Color fundus (CF) and fluo rescence angiography (FA) on d7 of representative eyes of the FN14 decoy receptor (upper panel) and the PBS group (lower panel) as well as confocal microscopy (CM) images of representative lesions (COL4 in red) the size of which approximately corresponds to the mean spot size within the respective group. (C): Protein concentrations of several cytokines on d5 in the RPE of unlasered controls, CNV injected with PBS (CNV) or with FN14 decoy receptor on d1 (CNV + decoy). Data are shown as mean with SEM. For statistical analysis, paired ANOVA adjusting for total protein concentration was applied. *: p < 0.05, ns: not significant.

Article Snippet: At d1 mice received an intravitreal injection of 4 μg FN14 decoy receptor (1610-TW, R&D Systems) solved in 1 μl PBS in one eye and the same volume of PBS in the other eye, as described above.

Techniques: Injection, Control, MANN-WHITNEY, Confocal Microscopy, Protein Concentration

cIAP-1 and cIAP-2 are downregulated in cholangiocytes of PSC patients. ( a ) Representative images of liver sections stained for cIAP-1 (left panel) and cIAP-2 (right panel) in patients with normal, NASH and PSC (stage IV) liver histology. Photomicrographs of small bile ducts (SBD) and large bile ducts (LBD) taken at × 20 magnification. The arrows point to the bile ducts. ( b ) Histological scoring for cIAP-1 in normal (5, 31), NASH (12, 120) and PSC (16, 131) patients and for cIAP-2 in normal (5, 31), NASH (12, 118) and PSC (16, 123) patients. Numbers in parentheses indicate total number of patients and total number of small and large bile ducts evaluated, respectively. Grade 0=no protein expression; grade 3=high protein expression. ** P <0.01, *** P <0.001. ( c ) Representative images of liver sections stained for TWEAK (left panel) and Fn14 (right panel) from patients with normal or PSC (stage IV) liver histology. Photomicrographs of small bile ducts and large bile ducts taken at × 40 and × 20 magnification, respectively. The arrows point to the bile ducts. ( d ) Immunoblot analysis showing expression of cIAP-1, cIAP-2 and actin (loading control) in H69 cells treated with human recombinant TWEAK (100 ng/ml) for the indicated times

Journal: Cell Death & Disease

Article Title: Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice

doi: 10.1038/cddis.2016.459

Figure Lengend Snippet: cIAP-1 and cIAP-2 are downregulated in cholangiocytes of PSC patients. ( a ) Representative images of liver sections stained for cIAP-1 (left panel) and cIAP-2 (right panel) in patients with normal, NASH and PSC (stage IV) liver histology. Photomicrographs of small bile ducts (SBD) and large bile ducts (LBD) taken at × 20 magnification. The arrows point to the bile ducts. ( b ) Histological scoring for cIAP-1 in normal (5, 31), NASH (12, 120) and PSC (16, 131) patients and for cIAP-2 in normal (5, 31), NASH (12, 118) and PSC (16, 123) patients. Numbers in parentheses indicate total number of patients and total number of small and large bile ducts evaluated, respectively. Grade 0=no protein expression; grade 3=high protein expression. ** P <0.01, *** P <0.001. ( c ) Representative images of liver sections stained for TWEAK (left panel) and Fn14 (right panel) from patients with normal or PSC (stage IV) liver histology. Photomicrographs of small bile ducts and large bile ducts taken at × 40 and × 20 magnification, respectively. The arrows point to the bile ducts. ( d ) Immunoblot analysis showing expression of cIAP-1, cIAP-2 and actin (loading control) in H69 cells treated with human recombinant TWEAK (100 ng/ml) for the indicated times

Article Snippet: Human recombinant TWEAK was from R&D Systems.

Techniques: Staining, Expressing, Western Blot, Recombinant